Format

Send to

Choose Destination
Curr Opin Psychiatry. 2010 Nov;23(6):574-81. doi: 10.1097/YCO.0b013e32833f46c9.

Cardiovascular aspects of antipsychotics.

Author information

1
Department of Psychiatry, Faculty of Medicine, University of Calgary, Calgary, Alberta, Canada. Thomas.raedler@albertahealthservices.ca

Abstract

PURPOSE OF REVIEW:

Schizophrenia is associated with increased mortality and reduced life expectancy, with cardiovascular disease being the most frequent cause of death. Antipsychotics have detrimental effects on different risk factors for cardiovascular disease. This review will focus on the relationship between antipsychotic treatment and cardiovascular disease.

RECENT FINDINGS:

The increased overall mortality and mortality from cardiovascular disease in schizophrenia are now well documented. Patients with schizophrenia are at risk of receiving less optimal treatment for cardiovascular disease. Patients with schizophrenia are at high risk of metabolic syndrome, a cluster of risk factors for cardiovascular disease. Some antipsychotics, in particular, clozapine and olanzapine, frequently cause weight gain, dyslipidemia and diabetes mellitus. Antipsychotics differ in their effects on body weight, lipids and glucose regulation. However, the long-term effects of these differences between individual antipsychotics on overall mortality and cardiovascular mortality are not well established.

SUMMARY:

More research is needed to better understand the relationship between schizophrenia, antipsychotic treatment and cardiovascular disease. More effective treatment strategies need to be developed to reduce the burden of cardiovascular disease in schizophrenia.

PMID:
20838345
DOI:
10.1097/YCO.0b013e32833f46c9
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Wolters Kluwer
Loading ...
Support Center